Severe Babesiosis in Hospital: Next-Line Management When Initial Treatment Fails to Resolve Infection

Severe babesiosis requiring hospital admission is a serious condition that can be complicated by marked anaemia, acute respiratory distress syndrome, disseminated intravascular coagulation, congestive heart failure, renal and liver impairment, shock, and other life-threatening complications. When hospitalised patients do not respond adequately to initial therapy, escalation to an alternative regimen is necessary.

Previous Treatment — Failure Condition

First-line management for hospitalised patients with acute severe babesiosis uses either atovaquone plus azithromycin or clindamycin plus quinine. The expected response is resolution of symptoms, a decrease in Babesia parasitaemia on peripheral blood smear to below 4%, and clearance of fever and parasites on smear within approximately one week. When symptoms worsen, parasitaemia increases, or these goals are not achieved, the first-line regimen is considered to have failed and an alternative approach is required.

Next-Line Approach (Partial Overview)

At this stage, management involves switching to alternative refractory regimens that incorporate azithromycin in combination with other agents — the complete protocol specifies which combination options apply and the clinical considerations that guide selection.

References
DOI: 10.1093/cid/ciab275
  • Severe babesiosis requires hospital admission and can be complicated by marked anemia, acute respiratory distress syndrome, disseminated intravascular coagulation, congestive heart failure, renal and liver impairment/failure, shock, splenic infarct or rupture, warm autoimmune hemolytic anemia, and/or fatal outcome.
  • Worsening of symptoms or increasing parasitemia despite azithromycin plus atovaquone followed by clindamycin and quinine should prompt consideration of an alternative antimicrobial regimen (Table 3).
View source ↗